---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-22-000017"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2022-05-23T23:59:59+00:00"
generated_at: "2026-06-25T08:28:09.374364+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Vertex Pharmaceuticals acquires Catalyst Biosciences' complement portfolio for $60 million

## Summary
- Vertex acquired Catalyst's complement portfolio and related IP, including CB 2782-PEG, for $60 million cash.
- The transaction closed on May 19, 2022, and was disclosed in an 8-K filed May 23, 2022.
- Vertex will record the $60 million purchase price in GAAP and non-GAAP operating expenses in Q2 2022.

## SEC filing metadata
- accession: 0000875320-22-000017
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2022-05-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532022000017/0000875320-22-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532022000017/vrtx-20220523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-22-000017
- JSON: https://secwatch.observer/filing/0000875320-22-000017.json
- Plain text: https://secwatch.observer/filing/0000875320-22-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.